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Abstract
Introduction The cytochrome P450 mitochondrial enzyme 25-
hydroxyvitamin D3 1α-hydroxylase (1α-hydroxylase) of renal
tubule cells hydroxylates the major circulating form of vitamin D
(25(OH)D3) to the active systemic hormone 1,25(OH)2D3.
Local production of 1,25(OH)2D3 appears to occur also at other
sites where 1α-hydroxylase is expressed for autocrine/paracrine
regulation. To reduce risks of hypercalcemia during treatment
with vitamin D, we have previously suggested use of non-1α-
hydroxylated vitamin D analogues to target tissues where 1α-
hydroxylase is expressed, including the parathyroid glands in
secondary hyperparathyroidism. The present study was
undertaken to examine expression of 1α-hydroxylase in breast
cancer and to investigate whether a non-1α-hydroxylated
vitamin D analogue displayed biological function. In addition,
expression of the 25-hydroxyvitamin D3 24-hydroxylase (24-
hydroxylase) and the vitamin D receptor (VDR) was investigated.
Methods The expression of 1α-hydroxylase, 24-hydroxylase and
VDR was investigated in breast cancer specimens (n = 19) and
normal breast tissues (n = 10) by immunohistochemistry and/or
RT-PCR. Consecutive cryosections of 6 µm essentially free of
immune cells were used in the analyses. The effect of vitamin D
analogues on transcriptional activation was analyzed in
transiently transfected MCF-7 breast cancer cells.
Results 1α-hydroxylase protein was demonstrated in 79% and
100% of breast cancer specimens and normal breast,
respectively. The overall relative mRNA levels of 1α-hydroxylase
and 24-hydroxylase in normal breast compared to breast tumors
were: 1α-hydroxylase, 1 ± 0.07 versus 0.7 ± 0.05, respectively
(p < 0.001); 24-hydroxylase, 1 ± 0.08 verus 2.1 ± 0.2,
respectively (p < 0.001). The VDR was expressed in 95% of the
tumors as expected, with mRNA levels of 1 ± 0.09 and 1.4 ±
0.12 (p < 0.05) in breast cancer and normal breast, respectively.
The ketoconazole-sensitive transcription activation potential of
the non-1α-hydroxylated vitamin D analogue prodrug of
EB1089 (EB1285) was demonstrated in MCF-7 cells, which
express 1α-hydroxylase. The activity of EB1285 was about 20%
of 1,25(OH)2D3.
Conclusion These results demonstrate nearly normal
expression levels of 1α-hydroxylase, 24-hydroxylase and VDR in
the majority of investigated breast cancer specimens. A non-1α-
hydroxylated vitamin D analogue displayed activity in breast
cancer cells. Such analogues may present future therapeutic
options for proliferative disorders where 1α-hydroxylase is
expressed.
Introduction
Breast cancer is considered the most frequent malignancy of
women in the western world. Surgery, radio-, chemo- and
endocrine therapies are used in the treatment or prevention of
this disease. During the past decade, the anticancer effects of
1,25(OH)2D3 and especially of the vitamin D analogue
EB1089 have been well documented in vitro and in vivo [1,2].
Exposing the breast cancer cell line MCF-7 to 1,25(OH)2D3 or
EB1089 elevates expression of the cell cycle restricting gene
p21, promotes the dephosphosphorylated form of the retino-
blastoma protein and keeps the cell in the G0-G1 stage of the
cell cycle [3,4]. In addition, growth regression and pro-apop-
totic effects of vitamin D analogues have been described in
breast cancer cell lines as well as in animal models of breastR980
1α-hydroxylase = 25-hydroxyvitamin D3 1α-hydroxylase; 24-hydroxylase = 25-hydroxyvitamin D3 24-hydroxylase; bp = base pairs; PTH = parathyroid 
hormone; VDR = vitamin D receptor
Breast Cancer Research    Vol 7 No 6    Segersten et al.
R981cancer without or in combination with chemo- or endocrine
therapy [5-12]. In a phase 1 clinical study, treatment with
EB1089 resulted in stabilized disease in 4 out of 14 patients
with advanced breast cancer [13].
The mitochondrial cytochrome P450 enzyme 25-hydroxyvita-
min D3 1α-hydroxylase (1α-hydroxylase) is the key enzyme in
systemic vitamin D activation [14,15]. Originally, 1α-hydroxy-
lase was considered as a renal enzyme, but is now known to
be expressed in many different tissues, such as the adrenal
medulla, brain, pancreas, placenta [16], parathyroid gland
[17], skin [14] and bone [18], with the possibility of local
1,25(OH)2D3 production and autocrine/paracrine regulation.
Additionally, 1α-hydroxylase activity is not only present in nor-
mal tissue but also in colorectal [19-23] and prostate cancer
[24-26]. Previously, we reported coincident increased expres-
sion of 1α-hydroxylase and reduced expression of 25-hydrox-
yvitamin D3 24-hydroxylase (24-hydroxylase) in the majority of
investigated parathyroid adenomas and secondary hyperplas-
tic glands from patients with primary- and secondary hyperpar-
athyroidism, respectively [17,27]. Based on these results we
suggested the use, in patients with hyperparathyroidism sec-
ondary to uremia, of non-1α-hydroxylated vitamin D analogues
that may become hydroxylated locally in parathyroid cells to an
active vitamin D receptor (VDR) binding compound with par-
athyroid hormone (PTH)suppressive and antiproliferative activ-
ities [27]. Here we have determined expression levels of 1α-
hydroxylase, 24-hydroxylase and VDR in breast cancer cells




Nineteen fresh frozen breast cancer specimens were ran-
domly selected from our tissue bank, stored at -70°C. Seven-
teen invasive ductal carcinoma and two invasive lobular
carcinoma were examined. Also, 10 apparently normal breast
tissue specimens from patients with breast cancer were
included in the analysis. Consecutive cryosections essentially
free of immune cells were used in the analyses. Informed con-
sent and approval of an ethical committee was given.
Immunohistochemistry
Acetone-fixed cryosections of 6 µm were immersed in 0.3%
(v/v) H2O2 in methanol and then blocked with an avidin-biotin
blocking kit (Vector Laboratories Inc., Burlingame, CA, USA)
or normal goat serum. The specific 1α-hydroxylase sheep pol-
yclonal peptide antiserum [17,28,29] or the VDR rabbit poly-
clonal peptide antiserum (sc-1008, Santa Cruz Biotechnology
Inc., Santa Cruz, California, USA) were applied to the tissue
sections and incubated at room temperature for 90 minutes
using dilutions of 1:50 or 1:400, respectively. As secondary
antibodies, the biotinylated donkey anti-sheep IgG (diluted 1/
500) or a biotinylated goat anti-rabbit IgG (diluted1/200) were
applied for 30 minutes, after which all sections were exposed
to an avidin-biotin complex (Vector Laboratories Inc.). The
immunoreaction was visualized with 3-amino-9-ethylcarbazole
and the sections were counterstained with Mayer's hematoxy-
lin. Tissue sections exposed to the 1α-hydroxylase antiserum
or VDR antiserum preincubated with an excess of 1α-hydrox-
ylase [17] or VDR (sc-1008P, Santa Cruz Biotechnology Inc.)
immunizing peptides were used as controls. In addition, the
1α-hydroxylase staining procedure was also performed on
acetone-fixed MCF-7 cells.
Isolation of total RNA and cDNA synthesis
Total RNA was extracted from 10 consecutive frozen sections
(6 µm) of the same tumor specimen (n = 19) and from normal
(n = 10) breast tissues using TRIzol Reagent (Invitrogen
Corp., Carlsbad, CA, USA) and treated with RQ1 DnaseI
(Promega, Madison, WI, USA) and proteinase K. One µg RNA
from each sample was reverse transcribed using a cDNA syn-
thesis kit (Amersham Biosciences, Uppsala, Sweden).
Semiquantitative RT-PCR analysis
Semiquantitative RT-PCR analysis was used for determination
of relative mRNA expression levels of 1α-hydroxylase, 24-
hydroxylase and VDR. 28S rRNA was used as internal stand-
ard [30]. The number of PCR cycles for each transcript was
determined according to what gave measurable PCR prod-
ucts in the linear range of PCR amplification. The following
mRNA-specific PCR primers were used: 1α-hydroxylase for-
ward primer, 5'-GCT ACA CGA GCT GCA GGT GCA GGG
C-3'; 1α-hydroxylase reverse primer, 5'-AGC GGG GCC
AGG AGA CTG CGG AGC C-3'; 24-hydroxylase forward
primer, 5'-GGC TTC TCC AGA AGA ATG CAG GGG ATG
AAG-3'; 24-hydroxylase reverse primer, 5'-TGA GGC TCT
TGT GCA GCT CGA CTG GAG TGA-3'; VDR forward
primer, 5'-TGC CTG ACC CTG GAG ACT TTG ACC-3'; VDR
reverse primer, 5'-CAT CAT GCC GAT GTC CAC ACA
GCG-3'. For 28S rRNA the forward primer 5'-GTT CAC CCA
CTA ATA GGG AAC GTG A-3' and reverse primer 5'-GGA
TTC TGA CTT AGA GGC GTT CAG T-3' were used [30]. The
sizes of the generated PCR products were 252 base pairs
(bp) for 1α-hydroxylase [17], 117 bp for 24-hydroxylase, 242
bp for VDR and 212 bp for 28S rRNA. The PCR fragments
displayed sequence identity to the published gene sequences
for 1α-hydroxylase (GenBank: AB006987), for 24-hydroxy-
lase (GenBank: NM_000782) and for VDR (GenBank:
NM_000376). All the PCR reactions contained 2 µl, except 1
µl for 24-hydroxylase, of the cDNA-reaction, 0.2 mM dNTP, 1
× PCR-buffer, 1.5 mM MgCl2, 1.25 U platinum DNA-polymer-
ase in a final volume of 50 µl. The primer concentrations were:
0.5 pmol/µl for 1α-hydroxylase; 0.2 pmol/µl for 24-hydroxy-
lase; 0.4 pmol/µl for VDR; and 0.4 pmol/µl for 28S rRNA. In
addition, the PCR reaction for 1α-hydroxylase contained 5%
dimethylsulphoxide. Thermal cycler conditions for 1α-hydroxy-
lase were: denaturation at 95°C for 1 minute, 38 cycles of
denaturation at 95°C for 20 s, annealing at 64°C for 20 s,
extension at 72°C for 20 s, followed by a final extension at
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cycler conditions were the same as for 1α-hydroxylase, except
for 24-hydroxylase (40 cycles performed with annealing at
60°C for 20 s) and VDR (denaturation at 95°C for 2 minutes,
38 thermal cycles and annealing at 61°C for 20 s). For 28S
rRNA, the thermal cycler conditions were denaturation at
95°C for 2 minutes and 20 cycles of denaturation at 95°C for
15 s, annealing at 66°C for 20 s followed by extension at 72°C
for 10 s. All the PCR reactions were performed in a GeneAmp
9700 thermal cycler (Applied Biosystems, New Jersey, USA).
After the indicated cycles of each amplification, 10 µl of each
PCR reaction was separated on a 2.0% agarose gel with
ethidium bromide. The intensity of each band was quantified
by Molecular Analysis software (Bio-Rad Lab., Richmond, CA,
USA). As negative controls, water was used instead of cDNA
product to reveal false positive reactions.
Transient transfection
MCF-7 cells were seeded at 2 × 105 cells per 35 mm dish on
the day before transfection. A luciferase reporter gene plasmid
(pMWM-30, MW Madsen, unpublished; 1 µg) with four cop-
ies of a DR3-type vitamin D response element from the rat
atrial natriuretic factor promoter [31], an expression vector for
VDR (pSG5-VDR; 0.5 µg) and the internal transfection control
CMV-LacZ (0.1 µg) were cotransfected in triplicate using
Fugene 6 (Roche Diagnostics Scandinavia AB, Bromma,
Sweden). Vehicle (ethanol), vitamin D analogues or ketocona-
zole were added 4 h post-transfection at the indicated con-
centrations. Cells were harvested 24 h later, and luciferase
and β-galactosidase activities were determined
luminometrically.
Statistical analysis
Unpaired Student's t-test was used and data were calculated
with Stat View 5.0 (SAS Institute Inc., Cary, NC, USA). Values
are presented as mean ± standard error of the mean.
Results
Expression of 1α-hydroxylase, 24-hydroxylase and VDR 
in breast cancer
Immunohistochemical analysis of 1α-hydroxylase expression
showed distinct cytoplasmic specific immunoreactivity for 14
of the 17 analyzed ductal breast cancer specimens, for one of
two lobular specimens and for all 10 normal breast tissues
(Fig. 1a,b,e,f). All three non-staining ductal cancers showed
specific immunoreactivity in the benign part of the specimen.
For both tumor and normal tissues, areas of variable size
showed intensely stained cells mixed with weakly or non-stain-
ing cells. 1α-hydroxylase was also found to be expressed in
the MCF-7 breast cancer cell line (Fig. 1g). In general, specific
VDR immunoreactivity appeared similar to 1α-hydroxylase but
also with weak nuclear staining (Fig. 1c,d). All analyzed spec-
imens, except for one ductal breast cancer and one normal
breast, stained for VDR.
Next, we determined the mRNA expression levels for 1α-
hydroxylase, VDR and 24-hydroxylase in relation to 28S rRNA.
We chose to use 28S rRNA as a comparative control because
glyceraldehyde-3-phosphate dehydrogenase is not
recommended in breast cancer [32]. Total RNA was isolated
from frozen sections of the same tumor (n = 19) and normal (n
= 10) breast tissues analyzed above. The results of the semi-
quantitative RT-PCR analysis are shown in Fig. 2. In compari-
Figure 1
Expression of 1α-hydroxylase in breast cancer. Immunohistochemical analysis of 1α-hydroxylase expression in (a) ductal breast cancer, (e) lobular 
breast cancer, (f) normal breast and (g) MCF-7 cells. (c) Expression of VDR in lobular breast cancer. Control sections were exposed to (b) 1α-
hydroxylase and (d) VDR peptide antisera pre-incubated with immunizing peptide.
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rRNA ratio (Fig. 2a) was somewhat lower (1 ± 0.07 versus 0.7
± 0.05, p < 0.001) and the VDR/28S rRNA ratio (Fig. 2B)
somewhat higher (1 ± 0.09 versus 1.4 ± 0.12, p < 0.05) in the
breast tumor specimens. Expression of 24-hydroxylase (Fig.
2c) was two-fold higher in the tumors compared to normal tis-
sues (2.1 ± 0.2 versus 1 ± 0.08, p < 0.001). These results
were consistent with the immunostainings of 1α-hydroxylase
and VDR. The three tissue specimens (two tumors, one nor-
mal) with no detected staining at all showed the lowest mRNA
expression levels for 1α-hydroxylase and VDR, respectively.
A non-1α-hydroxylated vitamin D analogue activates 
transcription in MCF-7 cells
We have recently suggested that inactive non-1α-hydroxy-
lated vitamin D analogues, with inherent low hypercalcemic
and hyperphosphatemic toxicity, could potentially become 1α-
hydroxylated locally in 1α-hydroxylase expressing cells and,
thereafter, execute biological functions by binding to the VDR
[27]. To test this idea experimentally in MCF-7 cells, we chose
the non-1α-hydroxylated form of EB1089 (Fig. 3a). This vita-
min D analogue (EB1285) is stable, has very low affinity for the
VDR and shows low calcemic effects [33] compared to
1,25(OH)2D3 in normal rats (Kaae Holm, unpublished). To
investigate biological activity of the non-1α-hydroxylated vita-
min D analogue EB1285, we performed a transient expression
analysis using a vitamin D response element-reporter gene
construct co-transfected together with a VDR expression vec-
tor and an internal transfection control plasmid. EB1285 acti-
vated transcription 89-fold from the VDRE reporter gene in
transfected MCF-7 cells at a concentration of 100 nM and 20-
fold at 10 nM (Fig. 3b). EB1089 displayed high potency, as
expected. Furthermore, in the presence of the cytochrome
P450 inhibitor ketoconazole, activation by EB1285 was
reduced by 50% (Fig. 3c), which would be expected [34] if
transcription activation was dependent on 1α-hydroxylase
enzymatic activity. EB1089 activated transcription to the same
extent regardless of ketoconazole addition (Fig. 3c), possibly
due to its resistance to inactivation by 24-hydroxylase activity
[35,36]. The transcriptional activity of EB1285 and EB1089,
compared to 1,25(OH)2D3 (EC50 = 1.0), was 0.2 and 105,
respectively (data not shown). The results support the idea
that an inactive non-1α-hydroxylated vitamin D analogue can
become hydroxylated and activated in cell culture (MCF-7),
although with low relative efficiency as shown here for
EB1285.
Discussion
In the present study, we have demonstrated 1α-hydroxylase
protein expression in 15 out of 19 (79%) analyzed breast can-
cer specimens, in 10 apparently normal breast biopsies from
breast cancer patients and also in MCF-7 cells. The observed
somewhat reduced overall 1α-hydroxylase mRNA expression
level as well as expression of VDR protein and mRNA in the
tumors were apparently consistent with the immunohisto-
chemical results, also indicating that representative mRNA
was isolated. Of the analyzed tumors, 95% stained for VDR, in
agreement with the 80% to 90% observed in earlier studies
[37,38].
The 24-hydroxylase mRNA level was overall two-fold higher in
breast carcinoma as compared to normal tissue. Notably, the
Figure 2
(a) Determination of 1α-hydroxylase, (b) VDR and (c) 24-hydroxylase mRNA xpression in normal (N) br ast tissue specimens (n = 10) and breast canc r (T) specimens (n = 19) by emiquantitative RT-PCR t r i ti  f - r x l , ( ) V R and (c) 24-hydroxylase 
mRNA expression in normal (N) breast tissue specimens (n = 10) and 
breast cancer (T) specimens (n = 19) by semiquantitative RT-PCR. The 
expression was related to the 28S rRNA level in each sample. The 
results are presented as mean ± standard error of the mean. and com-
parisons between the group means were analyzed by Student's t-test.
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gene [39].
Previous studies have demonstrated 1α-hydroxylation of the
prohormone 25(OH)D3 and inhibition of cell proliferation in
cultured prostate cancer cells expressing 1α-hydroxylase
[24,26]. 1α-hydroxylase is also expressed and active in color-
ectal cancer [20-23] and in ovarian cancer [40]. The non-cal-
cemic prohormone 25(OH)D3, which exhibits very low activity
in vitro and in vivo in the absence of 1α-hydroxylase [41,42],
has been considered a future preventive and/or therapeutic
option. A problem is rapid 24-hydroxylation and subsequent
degradation of 25(OH)D3 and of locally synthesized
1,25(OH)2D3. Use of more specific 24-hydroxylase inhibitors
[43] than liarozole and ketoconazole [34,44] may present
future therapeutic options. We reasoned that an alternative to
25(OH)D3 could be a non-1α-hydroxylated vitamin D analogue
[27], with a relative resistance to 24-hydroxylation by the 24-
hydroxylase. The activity of 1α-hydroxylase in the kidney is
tightly regulated by PTH and 1,25(OH)2D3 and even large
increases in serum 25(OH)D3 will not produce hypercalcemia
[25]. Similarily, local production of a VDR binding analogue by
hydroxylation would not be expected to cause the systemic
effect of hypercalcemia. Here we have shown that the non-1α-
hydroxylated prodrug of EB1089 (EB1285) could activate
transcription in MCF-7 cells, which express the 1α-hydroxy-
lase enzyme. The activation of transcription was ketoconazole-
sensitive, strongly suggesting that the observed effect was
due to 1α-hydroxylation. Thus, a vitamin D analogue could
constitute a substrate for the 1α-hydroxylase enzyme; how-
ever, EB1285 exhibited low transcription activation potential
compared to EB1089 in MCF-7 cells. This may indicate low
1α-hydroxylase enzyme activity in the cells and/or possibly
inefficient hydroxylation due to steric hindrance between sub-
strate and enzyme. Design of novel non-1α-hydroxylated vita-
min D analogues for the prevention or treatment of proliferative
disorders in which 1α-hydroxylase is expressed or induced is
warranted.
Conclusion
The findings imply that a vitamin D analogue could constitute
a substrate for the 1α-hydroxylase enzyme and that more effi-
cient non-1α-hydroxylated analogues should be considered
for treatment of human diseases in which 1α-hydroxylase is
expressed, such as breast cancer and secondary hyperparath-
yroidism [17,27].
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Figure 3
Transcription activity of EB1285 in MCF-7 cells. (a) The chemical 
structure of the vitamin D analogue EB1285 before and after (EB1089) 
1α-hydroxylation. (b) VDR-directed transcription activity of EB1089 or 
EB1285 in transfected MCF-7 cells. (c) Activation of transcription in 
the presence of the cytochrome P450 inhibitor ketoconazole. Asterisks 
represent p < 0.001.
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